This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/514055-johnsonjohnson-covid-vaccine-effective/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| Johnson & Johnson one-dose Covid-19 vaccine shown to be 66 percent effective against virus in phase 3 trials | Johnson & Johnson one-dose Covid-19 vaccine shown to be 66 percent effective against virus in phase 3 trials |
| (about 1 month later) | |
| The Covid-19 vaccine being developed by US company Johnson & Johnson has been found to be 66 percent effective at treating moderate and severe infections 28 days after vaccination, a large-scale phase 3 clinical trial has found. | The Covid-19 vaccine being developed by US company Johnson & Johnson has been found to be 66 percent effective at treating moderate and severe infections 28 days after vaccination, a large-scale phase 3 clinical trial has found. |
| The one-dose vaccine, made by Johnson & Johnson’s Belgian subsidiary Janssen, achieved 72 percent efficacy in preventing Covid-19 in US trials, while the lower success rate of 66 percent was observed in international trials, J&J said on Friday. | The one-dose vaccine, made by Johnson & Johnson’s Belgian subsidiary Janssen, achieved 72 percent efficacy in preventing Covid-19 in US trials, while the lower success rate of 66 percent was observed in international trials, J&J said on Friday. |
| The jab is less effective than those made by BioNTech-Pfizer, Moderna and Oxford-AstraZeneca, although the Janssen trials did exclude mild Covid-19 cases, meaning the accuracy of comparisons is limited. | The jab is less effective than those made by BioNTech-Pfizer, Moderna and Oxford-AstraZeneca, although the Janssen trials did exclude mild Covid-19 cases, meaning the accuracy of comparisons is limited. |
| Unlike other jabs, only one dose of Janssen’s vaccine is required, although extra trials to determine the efficacy of two doses are being carried out in the UK. | Unlike other jabs, only one dose of Janssen’s vaccine is required, although extra trials to determine the efficacy of two doses are being carried out in the UK. |
| “A one-shot vaccine is considered by the World Health Organization to be the best option in pandemic settings, enhancing access, distribution and compliance,” said Paul Stoffels, chief scientific officer at Johnson & Johnson. | “A one-shot vaccine is considered by the World Health Organization to be the best option in pandemic settings, enhancing access, distribution and compliance,” said Paul Stoffels, chief scientific officer at Johnson & Johnson. |
| Interim data for the Janssen jab also shows that it offers some protection against the 501.V2 Covid-19 variant first identified in South Africa late last year, which some scientists had worried could be resistant to vaccines. | Interim data for the Janssen jab also shows that it offers some protection against the 501.V2 Covid-19 variant first identified in South Africa late last year, which some scientists had worried could be resistant to vaccines. |
| Trials of the vaccine involved 43,783 participants and were conducted across three continents and in multiple countries, including South Africa, where efficacy was found to be 57 percent. | Trials of the vaccine involved 43,783 participants and were conducted across three continents and in multiple countries, including South Africa, where efficacy was found to be 57 percent. |
| No safety concerns have been reported for the vaccine and none of the participants required hospital treatment or died after taking it. | No safety concerns have been reported for the vaccine and none of the participants required hospital treatment or died after taking it. |
| The EU, which is currently facing a shortage of vaccines, has ordered at least 200 million doses of the Janssen jab, while the US has ordered 100 million, and the UK 30 million. | The EU, which is currently facing a shortage of vaccines, has ordered at least 200 million doses of the Janssen jab, while the US has ordered 100 million, and the UK 30 million. |
| On Friday, another vaccine made by US firm Novavax was found to be 89.3 percent effective at preventing Covid-19, according to data from phase 3 trials involving 15,000 people in the UK. | On Friday, another vaccine made by US firm Novavax was found to be 89.3 percent effective at preventing Covid-19, according to data from phase 3 trials involving 15,000 people in the UK. |
| The solution was also shown to be 86 percent effective at protecting against the B117 variant of Covid-19 discovered in the UK last year. The country has ordered 60 million doses of the jab. | The solution was also shown to be 86 percent effective at protecting against the B117 variant of Covid-19 discovered in the UK last year. The country has ordered 60 million doses of the jab. |
| Like this story? Share it with a friend! | Like this story? Share it with a friend! |